Icon of the Instituts for Quality and Efficiency in Health Care

Report

Bupropion, mirtazapine, and reboxetine in the treatment of depression

Status
Status: Commission completed
Project no.
A05-20C
Last updated

Report documents

  1. Executive summary of the final report version 1.1

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 236 kB, EN, not accessible
    Download file : Executive summary of the final report version 1.1 (PDF document, 236 kB, EN, not accessible)

  2. Final report version 1.1 (Erratum)

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 5 MB, DE, not accessible
    Download file : Final report version 1.1 (Erratum) (PDF document, 5 MB, DE, not accessible)

  3. Executive summary of the final report

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 287 kB, EN, not accessible
    Download file : Executive summary of the final report (PDF document, 287 kB, EN, not accessible)

  4. Final report

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 4 MB, DE, not accessible
    Download file : Final report (PDF document, 4 MB, DE, not accessible)

  5. Documentation and appraisal of comments on the preliminary report

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 6 MB, DE, not accessible
    Download file : Documentation and appraisal of comments on the preliminary report (PDF document, 6 MB, DE, not accessible)

  6. Executive summary of the preliminary report

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 237 kB, EN, not accessible
    Download file : Executive summary of the preliminary report (PDF document, 237 kB, EN, not accessible)

  7. Preliminary report

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    Download file : Preliminary report (PDF document, 2 MB, DE, not accessible)

  8. Report plan version 1.0

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 285 kB, DE, not accessible
    Download file : Report plan version 1.0 (PDF document, 285 kB, DE, not accessible)

  9. Documentation and appraisal of comments on the report plan and amendment 1

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    Download file : Documentation and appraisal of comments on the report plan and amendment 1 (PDF document, 1 MB, DE, not accessible)

  10. Amendment 1 to the report plan - preliminary version

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 43 kB, DE, not accessible
    Download file : Amendment 1 to the report plan - preliminary version (PDF document, 43 kB, DE, not accessible)

  11. Report plan - preliminary version

    Bupropion, mirtazapine, and reboxetine in the treatment of depression

    published on
    Document type
    PDF document, 299 kB, DE, not accessible
    Download file : Report plan - preliminary version (PDF document, 299 kB, DE, not accessible)

Press releases

Antidepressants: benefit of reboxetine not proven

However, bupropion XL and mirtazapine can benefit people suffering from depression
Press release

IQWiG calls for compulsory publication of all clinical trials

Manufacturers who conceal data are harming patients and hindering the work of IQWiG and the G-BA
Press release

Preliminary report on antidepressants published

Benefit of bupropion proven – Benefit of reboxetine not proven: manufacturer conceals study data
Press release

Pfizer conceals study data

Drug manufacturer hinders the best possible treatment of patients with depression
Press release

Additional information

IQWiG health information

There are various treatment options for depression. They include psychological treatments, medication and general measures such as relaxation techniques or the use of sports and exercise.

How is depression treated?

further information:

Information on studies of reboxetine

Project details

Project no.
A05-20C
Commission
Commission awarded on 22.02.2005 by the Federal Joint Committee (GBA).
Report type
Report
Status
Commission completed
Department/Division
Drug Assessment
Topic
Mental and emotional wellbeing

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page